J&J Expects Financial Ripple Effect From McNeil OTC Recall
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson expects the recall of pediatric liquid OTCs, including Tylenol and Motrin products, to diminish the firm's overall margins in addition to temporarily halting sales of some of its highest margin consumer products
You may also be interested in...
Silenor Deal Gives P&G Easy Access To Rx Market, Possible OTC Sales
Procter & Gamble's license to market the insomnia drug Silenor lets the firm re-enter the Rx drug market without development costs and opens the door to a potential OTC switch
Silenor Deal Gives P&G Easy Access To Rx Market, Possible OTC Sales
Procter & Gamble's license to market the insomnia drug Silenor lets the firm re-enter the Rx drug market without development costs and opens the door to a potential OTC switch
Silenor Deal Gives P&G Easy Access To Rx Market, Possible OTC Sales
Procter & Gamble's license to market the insomnia drug Silenor lets the firm re-enter the Rx drug market without development costs and opens the door to a potential OTC switch